AC Immune (ACIU) Return on Capital Employed (2016 - 2026)

AC Immune (ACIU) has 10 years of Return on Capital Employed data on file, last reported at 0.27% in Q1 2026.

• On a quarterly basis, Return on Capital Employed rose 4176.0% year-over-year to 0.27% in Q1 2026; TTM through Mar 2026 was 0.27%, a 4176.0% increase from a year earlier, with the FY2025 full-year figure at 0.07%, up 5001.0% from the prior year.
• Return on Capital Employed for Q1 2026 stood at 0.27%, up from 0.07% in the prior quarter.
• Over the last five years, Return on Capital Employed for ACIU reached as high as 0.71% in Q2 2022 and fell as low as 87.05% in Q3 2025.
• Historically, Return on Capital Employed has averaged 34.88% across 5 years, with a median of 38.93% in 2022.
• Across the five-year window, Return on Capital Employed slumped 8670 bps in 2022 and soared 4176 bps in 2026, its largest moves.
• Year by year, Return on Capital Employed stood at 38.93% in 2022, then soared by 101 bps to 0.39% in 2023, then tumbled by 9623 bps to 37.45% in 2024, then surged by 100 bps to 0.07% in 2025, then soared by 282 bps to 0.27% in 2026.
• Per Business Quant data, the three most recent Return on Capital Employed figures were 0.27% in Q1 2026, 0.07% in Q4 2025, and 87.05% in Q3 2025.